BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.800-3.100 for the period, compared to the consensus EPS estimate of 3.320. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN traded down $3.17 during mid-day trading on Tuesday, hitting $54.27. 841,899 shares of the stock traded hands, compared to its average volume of 2,105,241. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a market cap of $10.51 billion, a PE ratio of 146.97, a price-to-earnings-growth ratio of 0.61 and a beta of 0.22. The firm has a 50 day simple moving average of $60.43 and a two-hundred day simple moving average of $58.46.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.31. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 EPS. As a group, equities research analysts forecast that BioMarin Pharmaceutical will post 2.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday. Citigroup boosted their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. William Blair raised shares of BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Jefferies Financial Group upped their price target on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $60.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.09.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and broadly in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted EPS of $0.23 substantially exceeded the consensus estimate for a loss of approximately $0.08. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company expanded its pipeline with a new investigational Fabry-disease asset and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments support BioMarin’s longer-term growth prospects. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Citi reiterated a Buy rating, arguing that the timing-related setback does not undermine BioMarin’s long-term potential and citing approximately 32% upside. Other commentary described the stock as potentially undervalued following the Fabry deal and mixed guidance. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Negative Sentiment: BioMarin lowered fiscal 2026 EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and set revenue guidance at $3.8–$3.9 billion versus a $3.9 billion consensus. The lower outlook may outweigh the quarterly earnings beat in the near term. BMRN Q3 Deep Dive
• Neutral Sentiment: Management characterized the outlook issue as primarily related to order timing, while acquired IPR&D charges also affected earnings expectations. Investors will likely focus on whether demand timing normalizes and whether the expanded pipeline generates future growth.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.